SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
Status:
Completed
Trial end date:
2005-09-15
Target enrollment:
Participant gender:
Summary
RATIONALE: SU5416 may stop the growth of astrocytoma or glioma by stopping blood flow to the
tumor.
PURPOSE: Phase I/II trial to study the effectiveness of SU5416 in treating patients who have
recurrent astrocytoma or mixed glioma that has not responded to previous radiation therapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
North American Brain Tumor Consortium Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins